# FDA 483 - STgen Bio Co., Ltd. - June 25, 2024

Source: https://www.globalkeysolutions.net/records/483/stgen-bio-co-ltd/88b6c71d-4f82-4093-a06e-6f796291d3b3

> FDA 483 for STgen Bio Co., Ltd. on June 25, 2024. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: STgen Bio Co., Ltd.
- Inspection Date: 2024-06-25
- Product Type: drugs
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)

## Related Officers

- [Yiwei Li, Ph.D., Supervisory Chemist](https://www.globalkeysolutions.net/people/yiwei-li-phd-supervisory-chemist/25391f15-b3ee-400e-9e10-4fc2b674facc)
- [Chrigma Sherpa, Ph.D., Biologist](https://www.globalkeysolutions.net/people/chrigma-sherpa-phd-biologist/b86a5ffe-1d33-4ecd-a283-1a1f23cbc240)
- [Jeanne Fringer, Ph.D., Chemist](https://www.globalkeysolutions.net/people/jeanne-fringer-phd-chemist/c38f5762-9feb-4838-8624-6f213e06adbf)
- [Kathryn King, Ph.D., Research Biologist](https://www.globalkeysolutions.net/people/kathryn-king-phd-research-biologist/f39b79e2-2a18-4efa-9468-3c7471fabd86)

Company: https://www.globalkeysolutions.net/companies/stgen-bio-co-ltd/bf0530c2-b747-4fce-ade6-52850415aac3

Office: https://www.globalkeysolutions.net/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd